Oromandibular dystonia (OMD): A Prospective, Single-Blind Trial of AbobotulinumtoxinA (AboA)
Objective: To examine the safety and efficacy of AboA in OMD Background: OMD causes involuntary movements of the lower facial, masticatory, and lingual muscles. The…Saliva changes and the oral health in Parkinson´s disease
Objective: The aim of this study was to determine the risk of change in the oral microflora and oral health in PD patients. Background: Parkinson…Dosing of abobotulinumtoxinA and muscle selection in patients with simple patterns of cervical dystonia
Objective: To report international dosing practice for abobotulinumtoxinA (ABO) in a real-world pragmatic setting for the management of cervical dystonia (CD) with simple patterns. Background:…AbobotulinumtoxinA for cervical dystonia: International treatment patterns
Objective: To characterise international dosing practice for abobotulinumtoxinA (Dysport®, ABO) for cervical dystonia (CD) in a large observational study. Background: The safety and efficacy of…AbobotulinumtoxinA for cervical dystonia: A meta-analysis of injection practices across 5 countries
Objective: To explore national differences in the use of abobotulinumtoxinA (ABO) in the management of cervical dystonia (CD). Background: Botulinum toxin injections (including ABO) are…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.